世界の抗体薬物複合体(ADC)製造市場予測 2024-2032年

GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032

世界の抗体薬物複合体(ADC)製造市場予測 2024-2032年

The global antibody drug conjugates contract manufacturing market is estimated to progress at a CAGR of 12.47% during the forecast period 2024-2032.

世界の抗体薬物複合体(ADC)製造市場は、2024年から2032年の予測期間中に12.47%のCAGRで成長すると推定されています。

Numerous aspects stimulate the market growth: the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.

世界の抗体薬物複合体(ADC)製造市場予測 2024-2032年

 

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedPhase, Linker, and Condition
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedSterling Pharma Solutions, Recipharm AB, Lonza Group, Piramal Pharma Solutions, AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, Sartorius AG, WuXi Biologics, Samsung Biologics Co Ltd, Cambrex Corporation, Cerbios-Pharma SA